Semax: Evidence, Mechanism, Dosing & Legal Status

Semax is a Russian-developed synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro), an analog of the adrenocorticotropic hormone fragment ACTH(4-10) engineered to retain the peptide's neurotropic effects while shedding its hormonal activity.113 Registered as a prescription drug in Russia since 1994, it is marketed in fitness and nootropic circles abroad — but its rigorous human evidence is narrower than the enthusiasm suggests. This monograph separates the two.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Semax is not an FDA-approved drug; in the United States it is sold as a 'research chemical not for human use' and is prohibited in sport. Dosing figures are reported strictly as seen in the published literature and Russian clinical practice for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is Semax and how does it work?

Semax is a synthetic heptapeptide built by appending the C-terminal tripeptide Pro-Gly-Pro (PGP) to the ACTH(4-7) fragment of the larger ACTH(4-10) sequence (molecular formula C₃₇H₅₁N₉O₁₀S, MW ~813.9 g/mol).113 It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and first described around 1991. Critically, it lacks the sequence responsible for corticosteroid stimulation, so it has no ACTH hormonal activity while retaining the fragment's neurotropic actions.1

The core mechanism — best characterized in animals — is rapid, region-specific induction of neurotrophins. In rat hippocampus, a single 50 µg/kg dose produced about a 1.4-fold rise in BDNF protein, a 1.6-fold rise in TrkB phosphorylation, and roughly 2-3-fold increases in BDNF and TrkB mRNA.2 Intranasal Semax raised both BDNF and NGF in hippocampus with region-specific changes elsewhere — rapid, gene- and region-specific neurotrophin transcription.3 Downstream, BDNF acting on TrkB activates the MAPK/ERK, PI3K/Akt and PLCγ cascades that support neuronal survival, synaptic plasticity and neurogenesis. Semax's receptor mechanism is incompletely defined, with reported melanocortin MC4 and enkephalinase interactions of uncertain clinical significance.13

In permanent middle-cerebral-artery-occlusion rats, Semax and its metabolite PGP enhanced transcription of Bdnf, Ngf, Nt-3 and the Trk receptors in ischemic cortex; because ischemia alone downregulates neurotrophin receptors such as TrkB, this rescue in the penumbra is a plausible mechanistic basis for the stroke signal.47 Semax also markedly potentiated D-amphetamine's effect on extracellular dopamine and raised striatal serotonin metabolites without driving baseline tone — it amplifies stimulated monoaminergic signaling.56 The defining pharmacokinetic feature is a plasma-CNS disconnect: a plasma half-life of only minutes yet hours-to-days of CNS effect, attributed to the brain-persistent metabolite PGP, neurotrophin mRNA induction lasting 12-24 hours, and sustained enkephalinase inhibition.413

What is the evidence by indication?

Semax's evidence is unusually stratified — genuinely human for stroke, thinner for cognition, and theory-or-animal for everything else. The table below grades each indication honestly.

Stroke is the strongest human indication. A Russian-literature meta-analysis (screening 167 PubMed and 197 elibrary records to 8 studies, n=654) of intranasal Semax 1% at 12-18 mg/day in the first 10-14 days reported benefit on NIHSS, Rankin and Rivermead mobility outcomes.9 A rehabilitation trial in 110 post-stroke patients (mean age 58) using 6,000 µg/day in two 10-day courses raised plasma BDNF and accelerated Barthel Index recovery, with a positive BDNF-Barthel correlation.8 Animal MCAO data corroborate the neuroprotective mechanism.47 The caveat is real: these trials are small, predominantly Russian-language, variably blinded, and not replicated in large Western RCTs — graded B, not A, on that basis.

For cognition the human signal exists but is thin. Kaplan and colleagues reported that intranasal Semax (~16 µg/kg) improved attention and short-term memory in volunteers across the workday, with higher doses producing neuroprotective-like EEG changes.10 But the Alzheimer's Drug Discovery Foundation Cognitive Vitality review concludes the human cognition data are limited and methodologically weak, that benefit in healthy adults is sparse and inconclusive, and that evidence is insufficient to recommend Semax for cognitive enhancement.12 ADHD rests on a 2007 Medical Hypotheses paper — a theory, not a trial — plus uncontrolled pilot claims in children.11 Readers can confirm there is no completed, independent Western efficacy trial for any indication by searching ClinicalTrials.gov; the rigorous human record is the Russian stroke literature.

What doses appear in the literature?

Reported strictly as information, not a protocol or recommendation. Semax is supplied in Russia as 0.1% and 1% intranasal solutions; oral bioavailability is poor, so the intranasal (or subcutaneous) route is used.13 In acute ischemic stroke, reported dosing is roughly 9-18 mg/day of the 1% solution over the first 10-14 days, with meta-analysis-pooled protocols at 12-18 mg/day.9 The 110-patient rehabilitation trial used 6,000 µg/day in two 10-day courses with a 20-day interval.8 Cognition studies in healthy volunteers used about 16 µg/kg, with higher experimental doses of 250-1000 µg/kg producing EEG changes.10 Lower-intensity chronic neurological use as low as 600 µg/day for 10 days has been described.14 Because plasma half-life is minutes but neurotrophin effects last roughly 12-24 hours, dosing intervals in the literature reflect downstream signaling windows, not plasma kinetics — and research-chemical lyophilized powders have no standardized, regulator-vetted human reconstitution protocol.4

How safe is Semax?

Across Russian clinical use and trials Semax is generally reported as well tolerated, with many intranasal studies reporting no adverse effects.14 The most common adverse event is route-specific: mild nasal irritation, dryness or burning, which is dose- and formulation-dependent (1% more than 0.1%), with Russian prescribing information noting that about 10% of users may show mild changes of the nasal mucosa.14 Other reported effects include mild stimulation or anxiety at higher doses, sleep disturbance if dosed late, mild headache at cycle start, and a reported small subset (~7.4%) of diabetics with mild blood-glucose elevation.14 The larger issue is what is absent: no robust long-term or oncologic safety data, no independent Western pharmacovigilance, and impurity/aggregation risk from non-pharmaceutical research-chemical supply. Mechanistically Semax potentiates amphetamine-stimulated dopamine release in animals, so theoretical caution is warranted with stimulants and other CNS-active agents.5 Pregnancy and lactation have no safety data and should be avoided; pediatric use outside studied Russian contexts is unvalidated.

What is the FDA and WADA status in 2026?

Semax is not FDA-approved for any indication and is not currently on the §503A compounding bulk-substances list.17 Semax (free base and acetate) is scheduled for review by the FDA Pharmacy Compounding Advisory Committee on July 24, 2026 — alongside DSIP and Epitalon, with BPC-157, TB-500, KPV and MOTS-C on July 23 — under public docket FDA-2025-N-6895, noticed in the Federal Register on April 16, 2026.1516 A favorable PCAC recommendation followed by FDA listing would create a lawful §503A compounding pathway; absent that, it remains outside the approved-drug and compounding frameworks. In the US it is sold legally only as a research chemical 'not for human consumption' — unscheduled (no DEA control) but not lawfully marketable for human use.13 By contrast, Semax is a registered prescription drug in Russia (since 1994, and on Russia's List of Vital and Essential Drugs) and in Ukraine.13

For athletes the picture is unambiguous. Although Semax is not individually named on the WADA Prohibited List, as a pharmacological substance not approved by any government regulatory authority for human therapeutic use it falls within category S0 — Non-Approved Substances — and is prohibited at all times, with no Therapeutic Use Exemption.1819 Use can trigger an anti-doping violation even though the compound is purchasable as a research chemical, so any WADA-tested athlete or service member should treat Semax as banned.20

Bottom line. Semax pairs a well-mapped, biologically coherent mechanism — rapid BDNF/NGF/TrkB upregulation and penumbral receptor rescue — with genuine but single-country human data. What is reasonably evidenced is faster recovery and raised BDNF after acute ischemic stroke (Grade B); cognition is plausible but under-proven; ADHD and mood are hyped relative to the evidence. The key uncertainties are no large independent RCTs, no long-term or oncologic safety data, and research-chemical supply of uncertain purity. Treat current enthusiasm as ahead of the rigorous human evidence. Regulatory facts here are current as of June 2026; the July 24, 2026 PCAC outcome was pending at the time of writing and should be re-verified after that date.